Skip to main content

Table 3 Positivity of different triage tests for histologically negative (NEG), CIN1, CIN2, CIN3, and CC

From: Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping

 

NEG (n = 158) % (95% CI)

CIN1 (n = 79)

% (95% CI)

CIN2 (n = 26)

% (95% CI)

CIN3 (n = 50)

% (95% CI)

CC (n = 3)

% (95% CI)

HPV16/18+

72.2 (64.6–78.6)

68.4 (57.1–77.8)

65.4 (44.3–81.8)

60.0 (45.5–72.9)

100

ASCUS+

30.4 (23.6–38.1)

51.9 (40.7–62.9)

61.5 (40.7–78.9)

58.0 (43.6–71.2)

0

LSIL+

25.9 (19.7–33.4)

41.8 (31.2–53.1)

61.5 (40.7–78.9)

50.0 (36.0–64.0)

0

HSIL+

3.2 (1.3–7.4)

6.3 (2.6–14.6)

19.2 (7.7–40.4)

34.0 (21.9–48.6)

0

S5 at 3.7 cutoff

27.2 (20.8–34.8)

26.6 (17.9–37.6)

50.0 (30.5–69.5)

66.0 (51.4–78.1)

100

S5 at 0.8 cutoff

57.6 (49.7–65.4)

64.6 (53.2–74.5)

73.1 (51.7–87.3)

92.0 (79.9–97.1)

100

  1. ASCUS+ atypical squamous cells of undetermined significance or worse, HSIL+ high-grade squamous intraepithelial lesion or worse, LSIL+ low-grade squamous intraepithelial lesion or worse, NEG histologically negative, CIN cervical intraepithelial neoplasia (of grades 1, 2, and 3), CC cervical cancer